Toll Free No 1800 833 6699  | SMS DRBEST at 53456  |     Call us Monday - Saturday : 9:00 am - 6:30 pm  | Login / Register
DR LIPID 20

DR LIPID 20

₹16.00

PACK : Strip of 10 tablets.

Clear
SKU: N/A Categories: , Tag:

Product Description

COMPOSITION:  Each tablet  contains:-

Atorvastatin  20 mg

M.O.A. : 
Atorvastatin blocks the action of the enzyme (HMG-CoA reductase) that is required for the production of cholesterol in the body. It thus lowers the level of blood lipids such as cholesterol and triglycerides.

Pharmacodynamics :

The liver is the primary site of action of atorvastatin, as this is the principal site of both cholesterol synthesis and LDL clearance. It is the dosage of atorvastatin, rather than systemic drug concentration, which 
correlates with extent of LDL-C reduction.

Pharmacokinetics:

Absorption

Atorvastatin undergoes rapid absorption when taken orally, with an approximate time to maximum plasma concentration (Tmax) of 1–2 h. The absolute bioavailability of the drug is about 14%, but the systemic availability for HMG-CoA reductase activity is approximately 30%. Atorvastatin undergoes high intestinal clearance and first-pass metabolism, which is the main cause for the low systemic availability. Administration of atorvastatin with food produces a 25% reduction in Cmax (rate of absorption) and a 9% reduction inAUC (extent of absorption), although food does not affect the plasma LDL-C-lowering efficacy of atorvastatin. Evening dose administration is known to reduce the Cmax and AUC by 30% each. However, time of administration does not affect the plasma LDL-C-lowering efficacy of atorvastatin.

Distribution

The mean volume of distribution of atorvastatin is approximately 381 L. It is highly protein bound (≥98%), and studies have shown it is likely secreted into human breastmilk.

Metabolism

Atorvastatin metabolism is primarily through cytochrome P450 3A4 hydroxylation to form active ortho- and parahydroxylated metabolites, as well as various beta-oxidationmetabolites. The ortho- and parahydroxylated metabolites are responsible for 70% of systemic HMG-CoA reductase activity. The ortho-hydroxy metabolite undergoes further metabolism via glucuronidation. As a substrate for the CYP3A4 isozyme, it has shown susceptibility to inhibitors and inducers of CYP3A4 to produce increased or decreased plasma concentrations, respectively. This interaction was tested in vitro with concurrent administration of erythromycin, a known CYP3A4 isozyme inhibitor, which resulted in increased plasma concentrations of atorvastatin. It is also an inhibitor of cytochrome 3A4.

Excretion

Atorvastatin is primarily eliminated via hepatic biliary excretion, with less than 2% recovered in the urine. Bile elimination follows hepatic and/or extrahepatic metabolism. There does not appear to be any entero-hepatic recirculation. Atorvastatin has an approximate elimination half-life of 14 h. Noteworthy, the HMG-CoA reductase inhibitory activity appears to have a half-life of 20–30 h, which is thought to be due to the active metabolites. Atorvastatin is also a substrate of the intestinal P-glycoprotein efflux transporter, which pumps the drug back into the intestinal lumen during drug absorption.

In hepatic insufficiency, plasma drug concentrations are significantly affected by concurrent liver disease. Patients with A-stage liver disease show a four-fold increase in both Cmax and AUC. Patients with B-stage liver disease show a 16-fold increase in Cmax and an 11-fold increase in AUC.

Geriatric patients (>65 years old) exhibit altered pharmacokinetics of atorvastatin compared to young adults, with mean AUC and Cmax values that are 40% and 30% higher, respectively. Additionally, healthy elderly patients show a greater pharmacodynamic response to atorvastatin at any dose; therefore, this population may have lower effective doses.

INDICATION  : Mixed dyslipidaemia;Heterozygous familial hyoer-cholesterolaemia, Nonfamilial hypercholesterolaemia

DOSAGE:  As directed by the physician

SIDE EFFECTS : Fever, Extreme tiredness, Confusion and forgetfulness, Nausea, Heartburn, Indigestion, Muscle pain, Lack of energy, Joint pain, Diarrhoea.

 

SIMILAR PRODUCTS

Sr No SIMILAR PRODUCTS COMPANY MRP / Tab
1 Lipvas Cipla 220.20/10
2 Storvas Ranbaxy(CARDIOVASCULARS) 129.56/10
3 Atorlip Cipla 240.50/10
4 Aztor Sun Pharma Lab 188.05/10
5 Avas Micro Labs 254/10

Reviews

There are no reviews yet.

Be the first to review “DR LIPID 20”